Lynx Dx

01/12/2026

MyProstateScore 2.0 (MPS2) provides patients and providers with best-in-class accuracy.

And with MPS2, patients can screen for prostate cancer in the comfort of their home.

Read more about MPS2’s clinical validation in the Journal of Urology: https://www.lynxdx.com/2025/01/clinical-research-publications/mps2-clinical-validation-non-dre-urine/

01/06/2026

We're on the road this month! Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE required, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.
https://www.lynxdx.com/my-prostate-score/providers/

12/18/2025

New insights presented at show how reflex biomarker testing can lower over-detection and help providers make more confident biopsy decisions.

Click below to read how reflex biomarkers are key to guide next steps after an elevated PSA.

SUO 2025, Prostate Cancer, Over Detection in Prostate Cancer, Reflex Biomarkers in prostate cancer, urine biomarkers for prostate cancer, ProScreen.

12/10/2025

Lynx Dx is proud to sponsor Prostate Cancer Summit 2.0, presented by DrTalks.com. This five-day, online event brings together leading voices to empower men and their care teams with clarity on diagnosis, treatment options, and pathways to better outcomes.

On Day 2, our Chief Medical Officer, Spencer Heaton, will share how MyProstateScore 2.0 (MPS2) is advancing prostate cancer care by giving providers confidence to safely defer biopsy with proven best-in-class accuracy.

Whether you’re a patient seeking answers or a provider looking for the latest innovations, this summit offers valuable insights you won’t want to miss — Dec. 13-17.

Register for FREE today: https://drtalks.com/summit/prostate-cancer/

12/09/2025

Lynx Dx continues to advance innovation in prostate cancer diagnostics, with new findings presented last week at the Society of Urologic Oncology.

Learn more: https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4849

12/01/2025

We’re on the road this December!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://www.lynxdx.com/my-prostate-score/providers/

11/21/2025

A 2024 American Cancer Society survey found that two-thirds of men ages 55–69 aren’t being screened for prostate cancer.

For men with an elevated PSA or abnormal exam results, providers can use Lynx Dx's urine-based risk assessment, MyProstateScore 2.0 (MPS2), to help guide whether a biopsy is needed. And the urine sample can be collected at home or in the doctor’s office.

This , share this post to help us raise prostate cancer awareness!

Learn more: https://www.lynxdx.com/my-prostate-score/providers/

11/06/2025

MyProstateScore 2.0 (MPS2) works in conjunction with PSA testing and traditional risk calculators, providing patients and providers with best-in-class accuracy.

And with MPS2, patients can forgo the discomfort of a DRE and screen for prostate cancer in the comfort of their home.

Read more about MPS2’s clinical validation in the Journal of Urology: https://www.lynxdx.com/2025/01/clinical-research-publications/mps2-clinical-validation-non-dre-urine/

11/01/2025

We’re headed to Napa, CA this weekend for the Western Section of the American Urological Association, happening November 2-6!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

Learn more: https://www.lynxdx.com/my-prostate-score/providers/

10/24/2025

We’re proud to recognize the work of Dr. Arul Chinnaiyan, Lynx Dx's Co-Founder, and his colleagues at the University of Michigan, whose latest research uncovers a targeted strategy to inhibit prostate cancer growth through precision protein degradation.

This discovery reflects the same commitment to evidence-based innovation that led to the development of Lynx Dx's MyProstateScore 2.0 (MPS2), our next-gen, noninvasive test for prostate cancer risk assessment.

Read more about Dr. Chinnaiyan's research here: https://goodmenproject.com/featured-content/researchers-find-a-targeted-approach-to-shut-down-prostate-cancer-growth/

Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling

10/23/2025

Too many men put off prostate cancer screening.

At Lynx Dx, we’ve made screening for prostate cancer easy and stress-free. MyProstateScore 2.0 (MPS2) is a urine-based, noninvasive test that can be completed at-home or in-office.

Learn more here: https://www.LynxDx.com/my-prostate-score/providers/